Stockreport

Kymera Therapeutics Pivots to Immunology, Highlights KT-621 Data, Starts IRF5 Dosing; Runway to 2029 [Yahoo! Finance]

Kymera Therapeutics, Inc.  (KYMR) 
PDF immunology/inflammation, advancing six clinical IMiD degrader programs and reporting $1.6 billion in cash to fund operations into 2029. KT-621 (STAT6) progress: Phase [Read more]